Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The general purpose of this trial is to investigate the efficacy and safety of 4 dose
strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with
idiopathic pulmonary fibrosis.
The primary objective of this study is to demonstrate whether at least one dose strategy is
superior to placebo in patients with IPF, in modifying the rate of decline of Forced Vital
Capacity (FVC).
As a secondary objective, additional parameters will be assessed in order to differentiate
between dose strategies on the basis of safety and efficacy